Orthometrix, Inc.
OMRX
Rank in Stocks
#34755
Orthometrix, Inc., founded in 1993 and based in Naples, Florida, specializes in... Orthometrix, Inc., founded in 1993 and based in Naples, Florida, specializes in developing and distributing advanced technologies, methods, and devices aimed at enhancing musculoskeletal mobility. The company also focuses on providing non-invasive solutions to manage pain linked to conditions like osteoarthritis, plantar fasciitis, and other musculoskeletal issues that impede movement. Their product line encompasses a variety of offerings: Peripheral quantitative computed tomography (pQCT) systems, used for detailed bone and muscle measurement in both clinical and research environments. Patented motorized exercise systems, featuring unique vibration technology, designed for rehabilitation, physical therapy, and sports medicine applications. These are marketed to professional sports teams, fitness facilities, and the wellness-conscious public. Human performance measurement systems, which help track improvements in power and overall mobility. Extracorporeal shock wave therapy (ESWT) systems, offering non-invasive treatment for plantar fasciitis discomfort. Orthometrix provides sales and servicing for its range of products, which fall into categories such as bone and muscle diagnostics, research equipment, rehabilitation/physical therapy tools, sports and fitness gear, and home-use products. They serve a broad client base across the healthcare, veterinary, and sports & fitness sectors, both domestically in the United States and internationally. The company was previously known as Norland Medical Systems, Inc. before officially changing its name to Orthometrix, Inc. in April 2002.
Share Price
$0.0001
Last synced: 2026-11-06
Market Cap
$5.32K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Orthometrix, Inc. (OMRX)
Category
Healthcare
Operating Margin for Orthometrix, Inc. (OMRX)
Operating Margin as of November 2026 TTM: 17.22%
According to Orthometrix, Inc.'s latest financial reports, its current operating margin (TTM) is 17.22%. At the end of 2014 the company had an operating margin of 17.22%.
Operating Margin history for Orthometrix, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 17.22% | 0.00% |
| 2014 | 17.22% | 44.34% |
| 2013 | 11.93% | -153.93% |
| 2012 | -22.12% | -228.08% |
| 2007 | 17.27% | -75.17% |
| 2006 | 69.55% | -54.92% |
| 2005 | 154.29% | 9.91% |
| 2004 | 140.38% | 69.66% |
| 2003 | 82.74% | -52.55% |
| 2002 | 174.36% | 733.86% |
| 2001 | 20.91% | 65.69% |
| 2000 | 12.62% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 18.91% | -98.90% |
IE
|
|
| 10.95% | -99.36% |
CN
|
|
| 25.26% | -98.53% |
CH
|
|
| 13.54% | -99.21% |
CH
|
|
| 38.62% | -97.76% |
CN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Orthometrix, Inc.'s operating margin
What is Orthometrix, Inc.'s operating margin?
Orthometrix, Inc.'s operating margin is 17.22%, as of Nov 2026.
What was Orthometrix, Inc.'s operating margin in 2014?
In 2014, Orthometrix, Inc.'s operating margin was 17.22%, compared with 11.93% in 2013.
How has Orthometrix, Inc.'s operating margin changed since 2012?
From 2012 to 2014, Orthometrix, Inc.'s operating margin was highest in 2014 (17.22%) and lowest in 2012 (-22.12%).
How does Orthometrix, Inc.'s operating margin compare with similar companies?
Orthometrix, Inc.'s operating margin (17.22%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Jafron Biomedical Co.,Ltd., with 38.62%.